紫杉醇3周给药联合顺铂化疗对非小细胞肺癌患者miR-564、miR-219表达及预后的影响  

Effects of three-week paclitaxel administration combined with cisplatin chemotherapy on the expression and prognosis of miR-564 and miR-219 in patients with non-small cell lung cancer

作　　者：刘真 陈诚[2] LIU Zhen;CHEN Cheng(Department of Oncology,Sichuan Friendship Hospital,Chengdu 610066;Department of Thoracic Surgery,Pengzhou People’s Hospital,Chengdu 611930,Sichuan,China)

机构地区：[1]四川友谊医院肿瘤科,四川成都610066 [2]彭州市人民医院胸外科,四川成都611930

出　　处：《川北医学院学报》2023年第1期122-125,共4页Journal of North Sichuan Medical College

摘　　要：目的:分析紫杉醇3周给药联合顺铂化疗对非小细胞肺癌患者癌组织miR-564、miR-219表达及预后的影响。方法:将106例非小细胞肺癌患者,依据治疗方案不同分为观察组(n=53)和对照组(n=53)。观察组行紫杉醇3周给药联合顺铂化疗,紫杉醇第1天给药135~175 mg/m^(2),顺铂第2天给药75 mg/m^(2),21 d为1个周期;对照组行紫杉醇每周给药联合顺铂化疗,紫杉醇第1、8、15天给药,静脉滴注45~60 mg/m^(2),顺铂第2天给药,静脉滴注75 mg/m^(2),21 d为1个周期;两组均重复6个周期。治疗前后取两组的癌组织,以qRT-PCR法测定组织中miR-564和miR-219表达,并比较两组患者近期疗效、远期疗效和不良反应发生情况。结果:与治疗前比较,治疗后两组患者肺癌组织miR-219、miR-564表达水平均升高(P<0.05),但组间比较,差异均无统计学意义(P>0.05);两组近期疗效、1年生存率、复发率和转移率比较,差异均无统计学意义(P>0.05);两组不良反应比较,差异无统计学意义(P>0.05)。结论:紫杉醇3周与每周给药联合顺铂化疗方案都可以改善非小细胞肺癌患者癌组织miR-564、miR-219表达水平,但对患者近期疗效、远期疗效和不良反应影响无明显差异。Objective:To analyze the effects of three-week administration of paclitaxel combined with cisplatin chemotherapy on the expression and prognosis of miR-564 and miR-219 in patients with non-small cell lung cancer.Methods:106 patients with non-small cell lung cancer were divided into observation group(n=53) and control group(n=53) according to different treatment schemes.The observation group was given paclitaxel for three weeks combined with cisplatin chemotherapy.Paclitaxel was given 135-175 mg/m^(2) on the first day, and cisplatin was given 75 mg/m^(2) on the second day.21 days was a cycle.The control group received weekly paclitaxel plus cisplatin chemotherapy.Paclitaxel was administered on the 1,8 and 15 days, 45~60 mg/m^(2) intravenously, and cisplatin was administered on the second day, 75 mg/m^(2) intravenously.21 days was a cycle, and both groups repeated 6 cycles.The expressions of miR-564 and miR-219 in the cancer tissues of the two groups were detected by qRT-PCR before and after treatment, and the short-term efficacy, long-term efficacy and adverse reactions of the two groups were compared.Results:Compared with that before treatment, the expression levels of miR-219 and miR-564 in lung cancer tissues of the two groups increased after treatment(P<0.05),but there was no significant difference between the two groups(P>0.05).There was no significant difference in short-term efficacy, 1-year survival rate, recurrence rate and metastasis rate between the two groups(P>0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion:Paclitaxel for three weeks or weekly combined with cisplatin chemotherapy can improve the expression of miR-564 and miR-219 in non-small cell lung cancer patients, and there is no significant difference in short-term efficacy, long-term efficacy and adverse reactions.

关 键 词：紫杉醇联合顺铂化疗 非小细胞肺癌 miR-564 miR-219 给药周期 预后 

分 类 号：R734.2[医药卫生—肿瘤]